|
Apr 21
|
Why Sarepta Therapeutics And Other Genetics Stocks Just Got A Sizable Boost
|
|
Apr 9
|
Intellia Therapeutics, Inc. (NTLA): Among Stocks Under $10 that Will Triple
|
|
Feb 24
|
What's in Store for These 5 Biotech Stocks This Earnings Season?
|
|
Feb 24
|
2 Beaten-Down Stocks to Buy Before They Soar by 66% and 415%, According to Wall Street
|
|
Feb 20
|
Intellia Therapeutics (NTLA) Stock Jumps 6.5%: Will It Continue to Soar?
|
|
Feb 20
|
Intellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2024 Earnings and Company Updates
|
|
Feb 14
|
Intellia Therapeutics (NTLA): Among The Small–Cap Stocks Insiders Are Selling Recently
|
|
Feb 14
|
Does Intellia Therapeutics (NTLA) Have the Potential to Rally 422.41% as Wall Street Analysts Expect?
|
|
Dec 30
|
Why Is Intellia Therapeutics, Inc. (NTLA) Among the Top CRISPR Stocks to Invest In?
|
|
Dec 29
|
Intellia Therapeutics, Inc. (NTLA): Is This Gene Therapy Stock a Good Buy Right Now?
|
|
Oct 1
|
Intellia Therapeutics to Present New Clinical Data from the Phase 1 Study of nexiguran ziclumeran (nex-z) for the Treatment of Transthyretin (ATTR) Amyloidosis at the 2024 AHA Scientific Sessions
|
|
Sep 29
|
2 Innovative Cathie Wood Stocks to Buy If You Can Stomach the Risk
|
|
Jul 26
|
Intellia (NTLA) to Report Q2 Earnings: What's in the Cards?
|
|
Jul 24
|
Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
|
|
Jul 23
|
7 Biotech Stocks to Keep on Your Clinical Radar
|
|
Jun 17
|
Intellia Therapeutics to Present the First-Ever Clinical Data From Patients Redosed with an Investigational In Vivo CRISPR Gene Editing Therapy at the Peripheral Nerve Society Annual Meeting 2024
|
|
Jun 14
|
Intellia (NTLA) Banks on Genome Editing Pipeline Amid Rivalry
|
|
Jun 14
|
Intellia Therapeutics Names Brian Goff to its Board of Directors
|
|
Jun 9
|
Cathie Wood Goes Bargain Hunting: 2 Stocks She Just Bought
|
|
Jun 2
|
Intellia Therapeutics Announces Positive Long-Term Data from Ongoing Phase 1 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema (HAE)
|